Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Topotecan | The risk or severity of adverse effects can be increased when Satraplatin is combined with Topotecan. |
| Phenytoin | Satraplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosphenytoin | Satraplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Satraplatin is combined with Paclitaxel. |
| Docetaxel | The risk or severity of adverse effects can be increased when Satraplatin is combined with Docetaxel. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Satraplatin is combined with Cabazitaxel. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Satraplatin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Satraplatin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Satraplatin. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Satraplatin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Satraplatin. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Satraplatin is combined with Etrasimod. |